These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17495849)

  • 1. [The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration].
    Bregvadze IN; Maĭkov EB; Bil'dinov OA; Kratskina TL; Klimenko IuL; Smirnova MIu; Sokolov SF; Golitsyn SP; Rozenshtraukh LV; Chazov EI
    Kardiologiia; 2007; 47(3):48-55. PubMed ID: 17495849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation.
    Coleman CI; Sood N; Chawla D; Talati R; Ghatak A; Kluger J;
    Europace; 2009 Jul; 11(7):892-5. PubMed ID: 19351630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent.
    Patsilinakos S; Christou A; Kafkas N; Nikolaou N; Antonatos D; Katsanos S; Spanodimos S; Babalis D
    Am J Cardiol; 2010 Sep; 106(5):673-6. PubMed ID: 20723644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [First experience of clinical use of new class III antiarrhythmic agent niferidil in patients with persistent atrial fibrillation and flutter].
    Iuricheva IuA; Maĭkov EB; Sokolov SF; Klimenko IuL; Kratskina TL; Tarasovskiĭ GS; Bil'dinov OA; Bakalov SA; Golitsyn SP; Beloshapko GG; Iushmanova AV; Rozenshtraukh LV; Chazov EI
    Kardiologiia; 2011; 51(1):55-64. PubMed ID: 21626804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a new class III drug niferidil in cardioversion of persistent atrial fibrillation and flutter.
    Maykov EB; Yuricheva YA; Mironov NY; Sokolov SF; Golitsyn SP; Rosenshtraukh LV; Chazov EI
    J Cardiovasc Pharmacol; 2014 Sep; 64(3):247-55. PubMed ID: 24785342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter].
    Maykov EB; Yuricheva YA; Mironov NY; Sokolov SF; Golitsyn SP; Rozenshtraukh LV; Chazov EI
    Ter Arkh; 2015; 87(1):38-48. PubMed ID: 25823268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-injection of magnesium sulfate enhances the efficacy of ibutilide for the conversion of typical but not of atypical persistent atrial flutter.
    Steinwender C; Hönig S; Kypta A; Kammler J; Schmitt B; Leisch F; Hofmann R
    Int J Cardiol; 2010 Jun; 141(3):260-5. PubMed ID: 19136164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter.
    Tercius AJ; Kluger J; Coleman CI; White CM
    Pacing Clin Electrophysiol; 2007 Nov; 30(11):1331-5. PubMed ID: 17976094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR.
    Piccini JP; Pritchett EL; Davison BA; Cotter G; Wiener LE; Koch G; Feld G; Waldo A; van Gelder IC; Camm AJ; Kowey PR; Iwashita J; Dittrich HC
    Heart Rhythm; 2016 Sep; 13(9):1777-83. PubMed ID: 27108936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibutilide added to propafenone for the conversion of atrial fibrillation and atrial flutter.
    Chiladakis JA; Kalogeropoulos A; Patsouras N; Manolis AS
    J Am Coll Cardiol; 2004 Aug; 44(4):859-63. PubMed ID: 15312872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety.
    Gowda RM; Punukollu G; Khan IA; Wilbur SL; Vasavada BC; Sacchi TJ
    Am J Ther; 2003; 10(4):259-63. PubMed ID: 12845389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study].
    Zhang HC; Guo JH; Fang Q; Zheng YA; Sun YM; Zhu WQ; Wan Z; Guo JX; Ge JB; Han SM
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(12):798-801. PubMed ID: 15949393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.
    Glatter K; Yang Y; Chatterjee K; Modin G; Cheng J; Kayser S; Scheinman MM
    Circulation; 2001 Jan; 103(2):253-7. PubMed ID: 11208685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibutilide with magnesium for conversion of atrial fibrillation or flutter in rheumatic heart disease patients: Ibutilide with magnesium for chemical cardioversion of atrial fibrillation or flutter.
    Malviya A; Kapoor M; Sivam RKN; Khan SA; Pandey R; Kumar U; Ete T; Mishra A
    Indian Heart J; 2020; 72(4):283-288. PubMed ID: 32861384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter.
    Khitri AR; Aliot EM; Capucci A; Connolly SJ; Crijns H; Hohnloser SH; Kulakowski P; Roy D; Radzik D; Kowey PR
    J Cardiovasc Electrophysiol; 2012 May; 23(5):462-72. PubMed ID: 22171925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.
    Hongo RH; Themistoclakis S; Raviele A; Bonso A; Rossillo A; Glatter KA; Yang Y; Scheinman MM
    J Am Coll Cardiol; 2004 Aug; 44(4):864-8. PubMed ID: 15312873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of prophylactic i.v. magnesium on the efficacy of ibutilide for conversion of atrial fibrillation or flutter.
    Kalus JS; Spencer AP; Tsikouris JP; Chung JO; Kenyon KW; Ziska M; Kluger J; White CM
    Am J Health Syst Pharm; 2003 Nov; 60(22):2308-12. PubMed ID: 14652979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Conversion rate and prevention of recurrence of paroxysmal and sustained atrial fibrillation or atrial flutter with verapamil/quinidine].
    Trappe HJ; Pfitzner P
    Med Klin (Munich); 1996 Oct; 91(10):617-25. PubMed ID: 9019638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
    Banchs JE; Baquero GA; Nickolaus MJ; Wolbrette DL; Kelleman JJ; Samii S; Grando-Ting J; Penny-Peterson E; Davidson WR; Young SK; Naccarelli GV; Gonzalez MD
    Congenit Heart Dis; 2014; 9(3):221-7. PubMed ID: 23947935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nifekalant for acute conversion of atrial flutter: the possible termination mechanism of typical atrial flutter.
    Morita N; Tanaka K; Yodogawa K; Hayashi M; Akutsu K; Yamamoto T; Satoh N; Kobayashi Y; Katoh T; Takano T
    Pacing Clin Electrophysiol; 2007 Oct; 30(10):1242-53. PubMed ID: 17897127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.